Missing: CyberGene's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: CyberGene's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
CyberGene Web Traffic
CyberGene Frequently Asked Questions (FAQ)
When was CyberGene founded?
CyberGene was founded in 1995.
What is CyberGene's latest funding round?
CyberGene's latest funding round is Other Investors.
Who are the investors of CyberGene?
Investors of CyberGene include 3i Group and STING Capital.
Who are CyberGene's competitors?
Competitors of CyberGene include Akonni Biosystems, Integrated Nano-Technologies, Foundation Medicine, Pathwork Diagnostics, Knoesis and 11 more.
Compare CyberGene to Competitors
Adnavance Technologies Inc is developing enabling technology applications that use the conductivity properties of both normal and novel metallic forms of DNA aimed at large biosensormolecular diagnostics and energy generationmanagement markets
Molecular diagnostics device company developing automated instruments for nucleic acid purification (NAP) and nucleic acid testing (NAT). The company's first fully-integrated NAP system, the PGT 328, increases the efficiency and quality of nucleic acid purification using ProGenTech's designed disposable cartridges.
BioArray is a molecular diagnostics company engaged in the development and commercialization of assay solutions for multiplexed analysis of DNA and protein markers using a customizable bead array ("BeadChip") format and automated assay delivery system, with available products for immunohematology, transplantation, genetic testing and immunology.
Ativa Medical is a medical diagnostics company that is working to make diagnostic test results available in moments, rather than hours and days.
XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.
Quadraspec is changing the face of diagnostic medicine. Quadraspec's patented SDI label-free detection technology aims to permit the rapid analysis of up to 100 unique tests on up to 1,000 unique patients per hour. Quadraspec's , multiplex-capable diagnostics platform aims to allow high throughput, label-free, highly sensitive bioassays, and diagnostics.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.